Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas.
Immunohistochemistry
Metastatic
Paraganglioma
Pheochromocytoma
Somatostatin receptors
Succinate dehydrogenase B
Journal
Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
15
08
2018
revised:
07
11
2018
accepted:
17
11
2018
pubmed:
12
12
2018
medline:
20
11
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are neuroendocrine tumors that express somatostatin receptors (SSTRs), a phenomenon that constitutes a basis for tumor imaging and treatment with somatostatin analogues and peptide receptor radionuclide therapy. We studied the immunohistochemical expression of SSTR1-5 in 151 primary tumors, including 14 metastasized and 16 SDHB-deficient tumors. SSTR2 and SSTR3 were most abundantly present in these tumors, whereas the tumors were mostly negative for SSTR1, SSTR4, and SSTR5. All metastasized PGLs (9/9), but only one metastasized PHEO (1/5), were strongly SSTR2 positive. SSTR3 expression was lower in metastatic tumors and tumors with a high proliferation rate (MIB1 ≥ 5%), but tumors had variable individual SSTR profiles. No correlation was found between SDHB status and SSTR expression. Our results suggest that new SSTR analogues with affinity for several SSTRs could be relevant for a subgroup of patients with these tumors. Better knowledge of tumor SSTR profiles could open the door for personalized imaging and treatment in the future. Because SSTR profiles vary in PHEOs and PGLs, individual analysis is required for each tumor.
Identifiants
pubmed: 30529752
pii: S0046-8177(18)30474-X
doi: 10.1016/j.humpath.2018.11.020
pmc: PMC8192062
mid: NIHMS1703628
pii:
doi:
Substances chimiques
Receptors, Somatostatin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
66-75Subventions
Organisme : Intramural NIH HHS
ID : ZID BC011291
Pays : United States
Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Oncol Lett. 2017 Mar;13(3):1165-1174
pubmed: 28454229
J Surg Oncol. 2015 Dec;112(8):815-21
pubmed: 26464058
Adv Exp Med Biol. 2017;956:239-259
pubmed: 27888488
Mod Pathol. 2015 Jun;28(6):807-21
pubmed: 25720320
J Nucl Med. 2011 Dec;52 Suppl 2:42S-55S
pubmed: 22144555
Semin Diagn Pathol. 2013 Aug;30(3):207-23
pubmed: 24144290
Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1338-47
pubmed: 12937948
Eur J Endocrinol. 2016 Feb;174(2):241-50
pubmed: 26586796
Am J Surg Pathol. 2012 Feb;36(2):242-52
pubmed: 22251942
Oncotarget. 2015 Sep 29;6(29):27566-79
pubmed: 26259237
Endocr Relat Cancer. 2012 Sep 14;19(5):615-23
pubmed: 22736724
Drugs. 2015 May;75(8):847-58
pubmed: 25911185
Hum Pathol. 2015 Mar;46(3):390-6
pubmed: 25554089
Arch Pathol Lab Med. 2008 Aug;132(8):1272-84
pubmed: 18684026
Oncotarget. 2017 Sep 23;8(52):89958-89969
pubmed: 29163802
Mod Pathol. 2007 Nov;20(11):1172-82
pubmed: 17873898
Neuroendocrinology. 2015;101(1):45-57
pubmed: 25591947
Biomed Res Int. 2015;2015:917968
pubmed: 25879040
Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):31-6
pubmed: 23531856
Clin Endocrinol (Oxf). 2008 Jun;68(6):850-7
pubmed: 18031328
Endocr Rev. 2003 Aug;24(4):389-427
pubmed: 12920149
J Clin Endocrinol Metab. 2003 Nov;88(11):5150-7
pubmed: 14602742
Crit Rev Oncol Hematol. 2016 Apr;100:190-208
pubmed: 26839173
Curr Opin Endocrinol Diabetes Obes. 2017 Jun;24(3):174-183
pubmed: 28234804
Pancreas. 2016 Nov;45(10):1386-1393
pubmed: 27622342
Endocr Relat Cancer. 2015 Aug;22(4):T91-103
pubmed: 26273102
Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):19-31
pubmed: 26971841
Front Horm Res. 2004;31:145-54
pubmed: 14674309
J Clin Endocrinol Metab. 2013 Nov;98(11):E1730-9
pubmed: 24092823
Am J Surg. 2011 May;201(5):700-8
pubmed: 20870212